Fitness of drug resistant HIV-1: methodology and clinical implications.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Drug resistance updates

• Publication date

  2002-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1368-7646(02)00123-1PMID 12531179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Origin and Evolution of Viruses

  2010cited by this paper
• Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens.

  2002cited by this paper
• Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure

  2002cited by this paper
• In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

  2002cited by this paper
• Nelfinavir-Resistant, Amprenavir-Hypersusceptible Strains of Human Immunodeficiency Virus Type 1 Carrying an N88S Mutation in Protease Have Reduced Infectivity, Reduced Replication Capacity, and Reduced Fitness and Process the Gag Polyprotein Precursor Aberrantly

  2002cited by this paper
• Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors.

  2002cited by this paper
• Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

  2002cited by this paper
• "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

  2002cited by this paper
• Nonnucleoside Reverse Transcriptase Inhibitor Resistance

  2001cited by this paper
• Resistance to Protease Inhibitors

  2001cited by this paper
• A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.

  2001cited by this paper
• Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1

  2001cited by this paper
• Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

  2001influential reference
• Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

  2001cited by this paper
• Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

  2001cited by this paper
• A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV‐1 Reverse Transcriptase Variants

  2001cited by this paper
• Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles

  2001cited by this paper
• A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.

  2001cited by this paper
• Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

  2001cited by this paper
• Implications of antiretroviral resistance on viral fitness

  2001influential reference
• International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

  2001cited by this paper
• Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3

  2001cited by this paper
• Structured treatment interruptions in antiretroviral management of HIV-1

  2001cited by this paper
• Nucleoside Reverse Transcriptase Inhibitor Resistance

  2001cited by this paper
• Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations

  2001cited by this paper
• Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

  2001cited by this paper
• Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

  2001cited by this paper
• Impaired replication of protease inhibitor-resistant HIV-1 in human thymus

  2001cited by this paper
• International perspectives on antiretroviral resistance. Resistance to protease inhibitors.

  2001cited by this paper
• Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus

  2001cited by this paper
• Relative Replication Fitness of a High-Level 3′-Azido-3′-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thr→Gly) at Codon 69

  2000cited by this paper
• A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression

  2000cited by this paper
• Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.

  2000cited by this paper
• Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture

  2000cited by this paper
• Memory in Viral Quasispecies

  2000cited by this paper
• HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping Assays

  2000cited by this paper
• Patterns of Changes in Human Immunodeficiency Virus Type 1 V3 Sequence Populations Late in Infection

  2000cited by this paper
• Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.

  2000cited by this paper
• Altered Viral Fitness of HIV‐1 Following Failure of Protease Inhibitor‐Based Therapy

  2000cited by this paper
• Substantial Correlation between HIV Type 1 Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells in Treatment-Experienced Patients

  2000cited by this paper
• A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

  2000cited by this paper
• Determinants of virological response to antiretroviral therapy: implications for long-term strategies.

  2000cited by this paper
• HIV drug resistance and viral fitness.

  2000influential reference
• Viruses at the edge of adaptation.

  2000cited by this paper
• Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug

  2000cited by this paper
• Proposed alternatives for the use of anti-HIV drugs.

  1999cited by this paper
• Viral Quasispecies and Fitness Variations

  1999cited by this paper
• Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

  1999cited by this paper
• Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

  1999cited by this paper
• Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

  1999cited by this paper
• Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay

  1999cited by this paper
• Decreased Processivity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Containing Didanosine-Selected Mutation Leu74Val: a Comparative Analysis of RT Variants Leu74Val and Lamivudine-Selected Met184Val

  1999cited by this paper
• HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness

  1999cited by this paper
• Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1

  1999cited by this paper
• The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities

  1999cited by this paper
• Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy

  1998cited by this paper
• Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants

  1998cited by this paper
• Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients

  1998influential reference
• Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

  1998cited by this paper
• Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

  1998cited by this paper
• A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

  1998cited by this paper
• UvA-DARE (Digital Academic Repository) In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection

  1998cited by this paper
• Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

  1998cited by this paper
• Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation

  1997cited by this paper
• Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.

  1997cited by this paper
• Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

  1997cited by this paper
• A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors

  1997cited by this paper
• RNA virus mutations and fitness for survival.

  1997cited by this paper
• Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215

  1997cited by this paper
• Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients

  1996cited by this paper
• Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase

  1996cited by this paper
• Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

  1996cited by this paper
• Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

  1996cited by this paper
• Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants*

  1996cited by this paper
• Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.

  1995cited by this paper
• HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

  1995cited by this paper
• Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

  1995cited by this paper
• Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

  1994cited by this paper
• Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates

  1994cited by this paper
• Genetic Analysis of HIV-1 Isolates from Brazil Reveals Presence of Two Distinct Genetic Subtypes

  1994cited by this paper
• Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses

  1991cited by this paper

• Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART

  2024cites this paper
• QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro

  2024cites this paper
• Detecting Selection in the HIV-1 Genome during Sexual Transmission Events

  2022cites this paper
• Human Immunodeficiency Virus type 1 Drug Resistance Mutations in Patients Failing Antiretroviral Therapy in Lebanon from 2009 to 2013

  2021cites this paper
• A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells

  2021cites this paper
• Characterisation of HIV-1 subtype C envelope functional determinants of dual infected individuals

  2018cites this paper
• Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay

  2018cites this paper
• High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses

  2018cites this paper
• HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance

  2017cites this paper
• Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

  2017cites this paper
• Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

  2017cites this paper
• Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure

  2016cites this paper
• Investigating the fitness benefit of reverse transcriptase (RT) mutation A62V when co-occurring with M184V and K65R in HIV-1 subtype C

  2016cites this paper
• Mathematical modelling of host-disease-drug interactions in HIV disease

  2016cites this paper
• HIV Reverse Transcriptase Fidelity And Inhibition Are Modulated By Divalent Cations In A Concentration-Dependent Manner In Vitro

  2016cites this paper
• Adaptive Evolution of the SIV Envelope Protein During Early SIV Infection

  2016cites this paper
• Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations

  2015cites this paper
• A virus-envelope paired competitive assay to study entry efficiency of human immunodeficiency virus type 1 in vitro.

  2014cites this paper
• The Route of HIV Escape from Immune Response Targeting Multiple Sites Is Determined by the Cost-Benefit Tradeoff of Escape Mutations

  2014cites this paper
• The Roles of Stochasticity and Life History in the Evolutionary Population Dynamics of Pathogens

  2014cites this paper
• In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways

  2014cites this paper
• A Framework for Inferring Fitness Landscapes of Patient-Derived Viruses Using Quasispecies Theory

  2014cites this paper
• Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy

  2014cites this paper
• Estimating HIV-1 Fitness Characteristics from Cross-Sectional Genotype Data

  2014cites this paper
• Investigating the development and evolution of drug resistance in the HIV-1 pol gene

  2013cites this paper
• Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors

  2013influential citation
• Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors

  2013cites this paper
• Mechanisms of CCR5 Agonist/Antagonist Inhibition of HIV-1 Entry and In Vitro Selection of Virus Resistant to Maraviroc

  2013influential citation
• The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity

  2013cites this paper
• Roles of the K 101 E Substitution in HIV-1 Reverse Transcriptase in Resistance to 1 Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors 2 3

  2013cites this paper
• Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment.

  2013cites this paper
• Factors affecting relative fitness measurements in pairwise competition assays of human immunodeficiency viruses.

  2013cites this paper
• Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome

  2012cites this paper
• Contribution des protéines régulatrices Vif et Vpr du VIH-1 dans la résistance aux antirétroviraux chez des patients en échec virologique

  2012cites this paper
• HIV-1 antiretroviral drug therapy.

  2012cites this paper
• Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides

  2011cites this paper
• Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.

  2011cites this paper
• The role of the HIV-1 reverse transcriptase mutation H208Y to drug resistance and viral fitness

  2011cites this paper
• Generation of HIV-1 and Internal Control Transcripts as Standards for an In-House Quantitative Competitive RT-PCR Assay to Determine HIV-1 Viral Load

  2011cites this paper
• Generation of HIV-1 and Internal Control Transcripts as Standards for an In-House Quantitative Competitive RT-PCR Assay to Determine HIV-1 Viral Load

  2011cites this paper
• Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

  2011cites this paper
• Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy

  2011cites this paper
• Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.

  2010cites this paper
• Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.

  2010cites this paper
• Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction

  2010cites this paper
• Clinical management of HIV-1 resistance.

  2010cites this paper
• HIV-1 EVOLUTION: ROLE OF DIVERSITY AND FITNESS—IMPLICATIONS FOR THE EPIDEMIC

  2010cites this paper
• Delineation of the Preferences and Requirements of the Human Immunodeficiency Virus Type 1 Dimerization Initiation Signal by Using an In Vivo Cell-Based Selection Approach

  2010cites this paper
• Inhibitors of the Human Immunodeficiency Virus Protease

  2009cites this paper
• Evaluation of the NucliSens EasyQ HIV-1 v1.1 and RealTime HIV-1 kits for quantitation of HIV-1 RNA in plasma.

  2009cites this paper
• Developing best available evidence to inform healthy public policy.

  2009cites this paper
• Infectious disease modelling research progress

  2009cites this paper
• Mathematical Analysis of a Two Strain HIV/AIDS Model with Antiretroviral Treatment

  2009cites this paper
• HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.

  2008cites this paper
• Second generation HIV protease inhibitors against resistant virus

  2008cites this paper
• Exploring host -pathogen relationships through computer simulations of intracellular infection

  2008cites this paper
• The Human Immunodeficiency Virus Type 1 Envelope Confers Higher Rates of Replicative Fitness to Perinatally Transmitted Viruses than to Nontransmitted Viruses

  2008cites this paper
• Factors associated with different responses to combination antiretroviral therapy in an observational cohort study of HIV-1 infected patients

  2008cites this paper
• A new strategy based on recombinant viruses for assessing the replication capacity of HIV‐1

  2008cites this paper
• Perspectives and opportunities for novel antiviral treatments targeting virus fitness.

  2008cites this paper
• Viral drug resistance and fitness.

  2008cites this paper
• CHAPTER 15 – Clinical Implications of HIV Fitness and Virulence

  2008cites this paper
• Evaluation of Reverse Transcriptase Assay for Viral Load Monitoring

  2007cites this paper
• Estudio de carcterísticas fenotípicas del VIH mediante la generación y desarrollo de virus recombinantes: aplicación al estudio de la capacidad replicativa de virus multirresistentes

  2007cites this paper
• Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.

  2007cites this paper
• Is reduction of viral fitness a valid antiviral approach

  2007cites this paper
• Empleo de lopinavir-ritonavir durante tiempo prolongado en niños infectados por el virus de la inmunodeficiencia humana tipo 1 (VIH-1)

  2007cites this paper
• Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies

  2007cites this paper
• Superiority of infectivity-based over particle-based methods for quantitation of drug resistant HIV-1 as inocula for cell cultures.

  2007cites this paper
• Primary Isolates of Human Immunodeficiency Virus Type 1 Are Usually Dominated by the Major Variants Found in Blood

  2007cites this paper
• Emergence of Mammalian Cell-Adapted Vesicular Stomatitis Virus from Persistent Infections of Insect Vector Cells

  2007cites this paper
• Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

  2007cites this paper
• Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss

  2007cites this paper
• Virus fitness: concept, quantification, and application to HIV population dynamics.

  2006cites this paper
• Inverse Relationship between Viral Load and Genotypic Resistance Mutations in Korean Patients with Primary HIV Type 1 Infections

  2006cites this paper
• Quantitative SNP‐Detection Method for Estimating HIV‐1 Replicative Fitness: Application to Protease Inhibitor‐Resistant Viruses

  2006cites this paper
• Managing antiretroviral resistance

  2006cites this paper
• Issues in the design of trials comparing management strategies for heavily pretreated patients

  2006cites this paper
• Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness.

  2006cites this paper
• The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell.

  2006cites this paper
• Human immunodeficiency virus type 1 (HIV‐1) circulating recombinant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G

  2006cites this paper
• Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation

  2005cites this paper
• HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment.

  2005cites this paper
• Variaciones en el "fitness" del VIH-1 durante la Terapia Antirretroviral

  2005cites this paper
• Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression

  2005cites this paper
• Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression

  2005cites this paper
• Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides

  2005cites this paper
• The host environment drives HIV‐1 fitness

  2005cites this paper
• HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

  2005cites this paper
• HIV-1 virulence, fitness and replication capacity

  2005cites this paper
• Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy

  2004influential citation
• Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.

  2004cites this paper
• An algorithm‐based genotypic resistance score is associated with clinical outcome in HIV‐1‐infected adults on antiretroviral therapy

  2004cites this paper
• Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.

  2004cites this paper
• Can modulation of viral fitness represent a target for anti-HIV-1 strategies?

  2004cites this paper
• Antiretroviral therapy in Africa

  2004cites this paper
• Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

  2004cites this paper
• A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions*

  2004cites this paper
• Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations*

  2004cites this paper
• Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.

  2004cites this paper